A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

A Phase III Open-Label Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of MK0518/Raltegravir in a Diverse Cohort of HIV-Infected Patients

A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and at least 25% are female, either having received antiretroviral drugs before or not.

Inclusion Criteria:

• Patient is HIV positive
• Patient agrees to use (or have their partner use) birth control as defined by the study doctor

Exclusion Criteria:

• If female, pregnant or breastfeeding
• Patient has used an investigational agent in the last 30 days
• Patient has acute hepatitis
• Patient has received MK0518 (raltegravir) before
• Patient has used another experimental HIV-integrase inhibitor